1/16
01:00 am
bbio
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
Neutral
Report
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
1/15
11:32 am
bbio
BridgeBio's US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO [Yahoo! Finance]
Low
Report
BridgeBio's US$550 Million Notes Offering and ATTR-CM Push Could Be A Game Changer For BBIO [Yahoo! Finance]
1/15
06:21 am
bbio
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress [Yahoo! Finance]
Low
Report
Assessing BridgeBio Pharma (BBIO) Valuation After Attruby Uptake And Pipeline Progress [Yahoo! Finance]
1/14
04:10 pm
bbio
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 [Yahoo! Finance]
Low
Report
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 [Yahoo! Finance]
1/14
04:01 pm
bbio
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
Low
Report
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
1/12
05:02 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/12
10:30 am
bbio
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
1/9
10:31 am
bbio
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears [Yahoo! Finance]
Low
Report
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears [Yahoo! Finance]
1/8
12:20 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $86.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $86.00. They now have a "buy" rating on the stock.
1/6
11:46 pm
bbio
Is BridgeBio Pharma (BBIO) Pricing Reflect Long Term Potential After 156.5% One Year Surge [Yahoo! Finance]
Low
Report
Is BridgeBio Pharma (BBIO) Pricing Reflect Long Term Potential After 156.5% One Year Surge [Yahoo! Finance]
1/6
09:00 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $96.00 price target on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $96.00 price target on the stock.
1/6
08:02 am
bbio
BridgeBio Pharma Has 20% Upside Growth Potential, Morgan Stanley Says [Yahoo! Finance]
Low
Report
BridgeBio Pharma Has 20% Upside Growth Potential, Morgan Stanley Says [Yahoo! Finance]
1/5
07:54 am
bbio
BridgeBio to Participate in the J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
BridgeBio to Participate in the J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
07:30 am
bbio
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
Medium
Report
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
1/2
07:44 am
bbio
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET [Yahoo! Finance]
Low
Report
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET [Yahoo! Finance]
1/2
07:30 am
bbio
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
Low
Report
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
12/22
04:01 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/16
05:43 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) was upgraded by analysts at Sanford C. Bernstein to a "strong-buy" rating.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) was upgraded by analysts at Sanford C. Bernstein to a "strong-buy" rating.
12/15
03:46 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Leerink Partners from $75.00 to $86.00. They now have an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Leerink Partners from $75.00 to $86.00. They now have an "outperform" rating on the stock.
12/12
11:33 am
bbio
What Recent Clinical Wins Mean For BridgeBio Pharma's Evolving Growth Story [Yahoo! Finance]
Low
Report
What Recent Clinical Wins Mean For BridgeBio Pharma's Evolving Growth Story [Yahoo! Finance]
12/11
02:03 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating on the stock.
11/25
07:30 am
bbio
BridgeBio to Participate in December Investor Conferences
Low
Report
BridgeBio to Participate in December Investor Conferences
11/19
04:01 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
11/11
09:44 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $76.00 to $84.00. They now have an "overweight" rating on the stock.
Medium
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $76.00 to $84.00. They now have an "overweight" rating on the stock.
11/10
08:23 pm
bbio
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Medium
Report
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]